Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in Combination With Cytotoxic Chemotherapy for High-Risk Hematologic Malignancies
NCT05292664Phase 1Recruiting
- Start
- Mar 2023
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 2 more (3 cohorts). Primary endpoints: Maximum Tolerated Dose at 32 days, Recommended Phase II Dose at 32 days and 2 more. Started Mar 2023; status: recruiting.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on NCT05292664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05292664.